Immunokinases, a novel class of immunotherapeutics for targeted cancer therapy

Current Pharmaceutical Design

Volumn 15, Issue 23, 2009, Pages 2693-2699

  Tur, Mehmet Kemal ^a   Neef, Inga ^b   Jäger, Gernot ^a,b   Teubner, Andreas ^a   Stöcker, Michael ^a   Melmer, George ^c   Barth, Stefan ^a,b,c  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

^c PharmedArtis GmbH   (Germany)

Author keywords

Apoptosis; Autophagy; CaM kinases; Immunotherapy; Immunotoxins; Serine threonine protein kinases; Targeted cancer therapy; Therapeutic fusion protein

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CD30 LIGAND; DEATH ASSOCIATED PROTEIN KINASE; DEATH ASSOCIATED PROTEIN KINASE 1; DEATH ASSOCIATED PROTEIN KINASE 2; HYBRID PROTEIN; IMMUNOKINASE; IMMUNOTOXIN; PHOSPHOTRANSFERASE; PROTEIN KINASE; RECOMBINANT IMMUNOKINASE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER THERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SECRETION; CELL SPECIFICITY; DEPHOSPHORYLATION; DOWN REGULATION; DRUG POTENCY; ENZYME PHOSPHORYLATION; ENZYME STRUCTURE; EPIGENETICS; GENE EXPRESSION; GENETIC TRANSFECTION; HODGKIN DISEASE; HUMAN; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; MYELODYSPLASTIC SYNDROME; NONHUMAN; OVERALL SURVIVAL; PHYLOGENY; PRIORITY JOURNAL; REVIEW; SCID MOUSE; TUMOR CELL;

ANIMALS; ANTIGENS, CD30; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; HODGKIN DISEASE; HUMANS; IMMUNOTOXINS; MICE; MICE, SCID; MODELS, BIOLOGICAL; RECOMBINANT FUSION PROTEINS;

EID: 70350136720     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209788923877     Document Type: Review

References (73)

1. Maller JL. On the importance of protein phosphorylation in cell cycle control. Mol Cell Biochem 1993; 127-128: 267-81.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100(1): 57-70.
3. Barik S. Protein phosphorylation and signal transduction. Subcell Biochem 1996; 26: 115-64.
4. Graves JD, Krebs EG. Protein phosphorylation and signal transduction. Pharmacol Ther 1999; 82(2-3): 111-21.
5. Egan SE, Wright JA, Greenberg AH. Molecular determinants of metastatic transformation. Environ Health Perspect 1991; 93: 91-5.
6. Cross TG, Scheel-Toellner D, Henriquez NV, Deacon E, Salmon M, Lord JM. Serine/threonine protein kinases and apoptosis. Exp Cell Res 2000; 256(1): 34-41.
7. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002; 298(5600): 1912-34.
8. Hanks SK, Quinn AM, Hunter T. The protein kinase family: Conserved features and deduced phylogeny of the catalytic domains. Science 1988; 241(4861): 42-52.
9. Hanks SK, Quinn AM. Protein kinase catalytic domain sequence database: identification of conserved features of primary structure and classification of family members. Methods Enzymol 1991; 200: 38-62.
10. Bogre L, Okresz L, Henriques R, Anthony RG. Growth signalling pathways in Arabidopsis and the AGC protein kinases. Trends Plant Sci 2003; 8(9): 424-31.
11. Mora A, Komander D, van Aalten DM, Alessi DR. PDK1, the master regulator of AGC kinase signal transduction. Semin Cell Dev Biol 2004; 15(2): 161-70.
12. Zhu G, Fujii K, Liu Y, Codrea V, Herrero J, Shaw S. A single pair of acidic residues in the kinase major groove mediates strong substrate preference for P-2 or P-5 arginine in the AGC, CAMK, and STE kinase families. J Biol Chem 2005; 280(43): 36372-9.
13. Klimecka M, Muszynska G. Structure and functions of plant calcium-dependent protein kinases. Acta Biochim Pol 2007; 54(2): 219-33.
14. Knippschild U, Gocht A, Wolff S, Huber N, Lohler J, Stoter M. The casein kinase 1 family: Participation in multiple cellular processes in eukaryotes. Cell Signal 2005; 17(6): 675-89.
15. Knippschild U, Wolff S, Giamas G, Brockschmidt C, Wittau M, Wurl PU, et al. The role of the casein kinase 1 (CK1) family in different signaling pathways linked to cancer development. Onkologie 2005; 28(10): 508-14.
16. Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci 2005; 30(11): 630-41.
17. Malumbres M, Barbacid M. Cell cycle kinases in cancer. Curr Opin Genet Dev 2007; 17(1): 60-5.
18. Aparicio JG, Applebury ML. The photoreceptor guanylate cyclase is an autophosphorylating protein kinase. J Biol Chem 1996; 271(43): 27083-9.
19. Ward P, Equinet L, Packer J, Doerig C. Protein kinases of the human malaria parasite Plasmodium falciparum: The kinome of a divergent eukaryote. BMC Genomics 2004; 5(1): 79.
20. Mishra NS, Tuteja R, Tuteja N. Signaling through MAP kinase networks in plants. Arch Biochem Biophys 2006; 452(1): 55-68.
21. Tibes R, Trent J, Kurzrock R. Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. Annu Rev Pharmacol Toxicol 2005; 45: 357-84.
22. Gora-Tybor J, Robak T. Targeted drugs in chronic myeloid leukemia. Curr Med Chem 2008; 15(29): 3036-51.
23. Loh SH, Francescut L, Lingor P, Bahr M, Nicotera P. Identification of new kinase clusters required for neurite outgrowth and retraction by a loss-of-function RNA interference screen. Cell Death Differ 2008; 15(2): 283-98.
24. Goldberg JM, Manning G, Liu A, Fey P, Pilcher KE, Xu Y, et al. The dictyostelium kinome-analysis of the protein kinases from a simple model organism. PLoS Genet 2006; 2(3): E38.
25. Deiss LP, Feinstein E, Berissi H, Cohen O, Kimchi A. Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the gamma interferon-induced cell death. Genes Dev 1995; 9(1): 15-30.
26. Inbal B, Cohen O, Polak-Charcon S, Kopolovic J, Vadai E, Eisenbach L, et al. DAP kinase links the control of apoptosis to metastasis. Nature 1997; 390(6656): 180-4.
27. Inbal B, Shani G, Cohen O, Kissil JL, Kimchi A. Death-associated protein kinase-related protein 1, a novel serine/threonine kinase involved in apoptosis. Mol Cell Biol 2000; 20(3): 1044-54.
28. Cohen O, Feinstein E, Kimchi A. DAP-kinase is a Ca2+/ calmodulin-dependent, cytoskeletal-associated protein kinase, with cell death-inducing functions that depend on its catalytic activity. EMBO J 1997; 16(5): 998-1008.
29. Bialik S, Kimchi A. The death-associated protein kinases: Structure, function, and beyond. Annu Rev Biochem 2006; 75: 189-210.
30. Wang JH, Waisman DM. Calmodulin and its role in the second-messenger system. Curr Top Cell Regul 1979; 15: 47-107.
31. Krebs J. The role of calcium in apoptosis. Biometals 1998; 11(4): 375-82.
32. Braun AP, Schulman H. The multifunctional calcium/calmodulin-dependent protein kinase: From form to function. Annu Rev Physiol 1995; 57: 417-45.
33. Shani G, Henis-Korenblit S, Jona G, Gileadi O, Eisenstein M, Ziv T, et al. Autophosphorylation restrains the apoptotic activity of DRP-1 kinase by controlling dimerization and calmodulin binding. Embo J 2001; 20(5): 1099-113.
34. Inbal B, Bialik S, Sabanay I, Shani G, Kimchi A. DAP kinase and DRP-1 mediate membrane blebbing and the formation of autophagic vesicles during programmed cell death. J Cell Biol 2002; 157(3): 455-68.
35. Gozuacik D, Kimchi A. Autophagy as a cell death and tumor suppressor mechanism. Oncogene 2004; 23(16): 2891-906.
36. Shohat G, Spivak-Kroizman T, Cohen O, Bialik S, Shani G, Berrisi H, et al. The pro-apoptotic function of death-associated protein kinase is controlled by a unique inhibitory autophosphorylation-based mechanism. J Biol Chem 2001; 276(50): 47460-7.
37. Kawai T, Nomura F, Hoshino K, Copeland NG, Gilbert DJ, Jenkins NA, et al. Death-associated protein kinase 2 is a new calcium/ calmodulin-dependent protein kinase that signals apoptosis through its catalytic activity. Oncogene 1999; 18(23): 3471-80.
38. Bialik S, Berissi H, Kimchi A. A high throughput proteomics screen identifies novel substrates of death-associated protein kinase. Mol Cell Proteomics 2008; 7(6): 1089-98.
39. Raveh T, Droguett G, Horwitz MS, DePinho RA, Kimchi A. DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation. Nat Cell Biol 2001; 3(1): 1-7.
40. Kimchi A. A cell death-promoting kinase. Nat Struct Biol 2001; 8(10): 824-6.
41. Rizzi M, Tschan MP, Britschgi C, Britschgi A, Hugli B, Grob TJ, et al. The death-associated protein kinase 2 is up-regulated during normal myeloid differentiation and enhances neutrophil maturation in myeloid leukemic cells. J Leukoc Biol 2007; 81(6): 1599-608.
42. Tur MK, Neef I, Jost E, Galm O, Jäger G, Stöcker M, et al. Targeted Restoration of Downregulated DAPK2 Tumor Suppressor Activity Induces Apoptosis in Hodgkin Lymphoma cells J Immunother 2009; in press.
43. Raveh T, Kimchi A. DAP kinase-a proapoptotic gene that functions as a tumor suppressor. Exp Cell Res 2001; 264(1): 185-92.
44. Katzenellenbogen RA, Baylin SB, Herman JG. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood 1999; 93(12): 4347-53.
45. Raval A, Tanner SM, Byrd JC, Angerman EB, Perko JD, Chen SS, et al. Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell 2007; 129(5): 879-90.
46. Bai T, Tanaka T, Yukawa K, Maeda M, Umesaki N. Reduced expression of death-associated protein kinase in human uterine and ovarian carcinoma cells. Oncol Rep 2004; 11(3): 661-5.
47. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349(21): 2042-54.
48. Kissil JL, Feinstein E, Cohen O, Jones PA, Tsai YC, Knowles MA, et al. DAP-kinase loss of expression in various carcinoma and B-cell lymphoma cell lines: Possible implications for role as tumor suppressor gene. Oncogene 1997; 15(4): 403-7.
49. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Kohler G, Wijermans P, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 2002; 100(8): 2957-64.
50. Silverman LR, Mufti GJ. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome. Nat Clin Pract Oncol 2005; 2(Suppl 1): S12-23.
51. Esteller M. DNA methylation and cancer therapy: New developments and expectations. Curr Opin Oncol 2005; 17(1): 55-60.
52. Hackanson B, Bennett KL, Brena RM, Jiang J, Claus R, Chen SS, et al. Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia. Cancer Res 2008; 68(9): 3142-51
53. Friedmann T. Gene therapy of cancer through restoration of tumor-suppressor functions? Cancer 1992; 70(6 Suppl): 1810-7.
54. Bowen C, Birrer M, Gelmann EP. Retinoblastoma protein-mediated apoptosis after gamma-irradiation. J Biol Chem 2002; 277(47): 44969-79.
55. Levine AJ, Wu MC, Chang A, Silver A, Attiyeh EF, Lin J, et al. The spectrum of mutations at the p53 locus. Evidence for tissue-specific mutagenesis, selection of mutant alleles, and a "gain of function" phenotype. Ann N Y Acad Sci 1995; 768: 111-28.
56. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007; 445(7128): 661-5.
57. Wang W, El-Deiry WS. Restoration of p53 to limit tumor growth. Curr Opin Oncol 2008; 20(1): 90-6.
58. Morita S, Iida S, Kato K, Takagi Y, Uetake H, Sugihara K. The synergistic effect of 5-aza-2′-deoxycytidine and 5-fluorouracil on drug-resistant tumors. Oncology 2006; 71(5-6): 437-45.
59. Huhn M, Sasse S, Tur MK, Matthey B, Schinkothe T, Rybak SM, et al. Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma. Cancer Res 2001; 61(24): 8737-42.
60. Barth S, Tur MK, Stöcker M, Fischer R, inventors; Immunokinases patent WO2005068616 (A2). 2005.
61. Smith CA, Gruss HJ, Davis T, Anderson D, Farrah T, Baker E, et al. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1993; 73(7): 1349-60.
62. Herszfeld D, Wolvetang E, Langton-Bunker E, Chung TL, Filipczyk AA, Houssami S, et al. CD30 is a survival factor and a biomarker for transformed human pluripotent stem cells. Nat Biotechnol 2006; 24(3): 351-7.
63. Wiley SR, Goodwin RG, Smith CA. Reverse signaling via CD30 ligand. J Immunol 1996; 157(8): 3635-9.
64. Klimm B, Schnell R, Diehl V, Engert A. Current treatment and immunotherapy of Hodgkin's lymphoma. Haematologica 2005; 90(12): 1680-92.
65. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002; 1(7): 493-502.
66. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer 2006; 6(7): 559-65.
67. Pagano L, Fianchi L, Caira M, Rutella S, Leone G. The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients. Oncogene 2007; 26(25): 3679-90.
68. Kreitman RJ. Confirmation and prevention of targeted toxicity by a recombinant fusion toxin. Mol Cancer Ther 2004; 3(12): 1691-2.
69. Debatin KM. Chronic lymphocytic leukemia: Keeping cell death at bay. Cell 2007; 129(5): 853-5.
70. Barth S, Huhn M, Matthey B, Tawadros S, Schnell R, Schinkothe T, et al. Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice. Blood 2000; 95(12): 3909-14.
71. Grant KM. Targeting the cell cycle in the pursuit of novel chemotherapies against parasitic protozoa. Curr Pharm Des 2008; 14(9): 917-24.
72. Muller BA. Imatinib and its successors - how modern chemistry has changed drug development. Curr Pharm Des 2009; 15(2): 120-33.
73. Wu X, Lee VC, Chevalier E, Hwang ST. Chemokine receptors as targets for cancer therapy. Curr Pharm Des 2009; 15(7): 742-57.